Mid
S
SNDXAI Stock Diagnostic Report
Syndax plummets as IPF asset axatilimab fails in phase 2 trial
Syndax's IPF treatment axatilimab failed in a Phase 2 trial, causing its stock price to plummet.
View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
SNDX Analysis History (Last 30 Days)